Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of LM-168 in combination with other antitumor therapies in advanced solid tumors
CTR20262362Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-168 in Nonhematologic neoplasms, sponsored by LaNova Medicines. Started Jul 2026; status: active.
02
Drugs
LM-168
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20262362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262362.